Organization
Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new approach to base editing.
NICE Recommends NHS England Provide AstraZeneca's Tagrisso for Adjuvant EGFR-Mutated NSCLC
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
Guardant Health Reveal Assay Gets Additional Medicare Coverage for CRC Surveillance Testing
The test was previously covered for use in colorectal cancer patients in the early postsurgical setting only.
Atara Biotherapeutics Receives FDA Complete Response Letter for Ebvallo
The FDA didn't approve the therapy in EBV-positive posttransplant lymphoproliferative disease due to findings at a third-party manufacturing facility.